2. Search Result
Search Result
Results for "

IL-17A inhibitor

" in MedChemExpress (MCE) Product Catalog:

37

Inhibitors & Agonists

10

Inhibitory Antibodies

2

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-139686
    IL-17A inhibitor 2

    		Interleukin Related Inflammation/Immunology
    IL-17A inhibitor 2 is an IL-17A inhibitor for researching psoriasis, rheumatoid arthritis, and multiple sclerosis.
    IL-17A inhibitor 2
  • HY-139206
    LY3509754
    3 Publications Verification

    IL-17A inhibitor 1

    		 Interleukin Related Inflammation/Immunology
    LY3509754 (IL-17A inhibitor 1) is a IL-17A inhibitor, with IC50 values of <9.45 nM and 9.3 nM in alphalisa assay and HT-29 cells .
    LY3509754
  • HY-145429
    IL-17A modulator-2
    2 Publications Verification

    		 Interleukin Related Neurological Disease Inflammation/Immunology Cancer
    IL-17A modulator-2 is a IL-17A modulator, extracted from patent WO2021239743+A1, example 27. IL-17A modulator-2 inhibits the biological action of IL-17A with a pIC50 of 8.3. IL-17A modulator-2 can be used for the research of diseases or disorders associated with modulation of IL-17A activity including diseases with an immune component or autoimmune pathol, cancer and neurodegenerative disorders .
    IL-17A modulator-2
  • HY-145430
    IL-17A modulator-1

    		Interleukin Related Neurological Disease Inflammation/Immunology Cancer
    IL-17A modulator-1 is a IL-17A modulator, extracted from patent WO2021239743+A1, example 9. IL-17A modulator-1 inhibits the biological action of IL-17A with a pIC50 of 8.2. IL-17A modulator-1 can be used for the research of diseases or disorders associated with modulation of IL-17A activity including diseases with an immune component or autoimmune pathol, cancer and neurodegenerative disorders .
    IL-17A modulator-1
  • HY-P990222
    Anti-Mouse/Rat IL-17A Antibody (17F3)

    		Interleukin Related Others
    Anti-Mouse/Rat IL-17A Antibody (17F3) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse/rat IL-17A.
    Anti-Mouse/Rat IL-17A Antibody (17F3)
  • HY-P99335
    Vunakizumab

    Anti-Human IL17A Recombinant Antibody

    		 Interleukin Related Inflammation/Immunology
    Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis .
    Vunakizumab
  • HY-169306
    IL-17A inhibitor 4

    		Interleukin Related Inflammation/Immunology
    IL-17A inhibitor 4 (Example 449) is a potent IL-17A inhibitor. IL-17A inhibitor 4 inhibits HTRF and NHK cells viability with IC50s of 0.028 and 0.0047 μM, respectively .
    IL-17A inhibitor 4
  • HY-148272
    IL-17A modulator-3

    		Interleukin Related Inflammation/Immunology Cancer
    IL-17A modulator-3 (compound 253) is a IL-17A modulator. IL-17A modulator-3 inhibits IL-17A/A with an IC50 value ＜10 μM. IL-17A modulator-3 can be used for the research of inflammation, cancer and autoimmune disease .
    IL-17A modulator-3
  • HY-P991091
    COVA322

    		TNF Receptor Interleukin Related Inflammation/Immunology
    COVA322 is a bispecific TNF and IL-17A antibody. COVA322 inhibits simultaneously TNF and the IL-17A homodimer that can be used for the study of inflammatory diseases .
    COVA322
  • HY-158159
    IL17A-IN-1

    		Interleukin Related Inflammation/Immunology Cancer
    IL17A-IN-1 (compound 72) is an orally active Interleukin 17A inhibitor. IL17A-IN-1 can be used in the study of inflammatory and autoimmune diseases (plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, etc.), as well as cancer .
    IL17A-IN-1
  • HY-153780
    Navepdekinra

    		Interleukin Related Inflammation/Immunology
    Navepdekinra (Example 210) is a potent interleukin-17A (IL-17A) inhibitor with anti-inflammatory activity .
    Navepdekinra
  • HY-N12481
    Cephalandole B

    		Others Inflammation/Immunology
    Cephalandole B is an indigo alkaloid that has the activity of inhibiting IL-17A gene expression. Cephalandole B significantly inhibited the activity of IL-17A luciferase reporter gene in Jukat cells, and this inhibitory effect was dose-dependent. Cephalandole B may have important application prospects in inflammation-related research .
    Cephalandole B
  • HY-P99515
    Xeligekimab

    GR 1501

    		 Interleukin Related Inflammation/Immunology
    Xeligekimab (GR 1501) is an anti-human interleukin 17A (IL-17A) humanized monoclonal antibody. Xeligekimab inhibits the pro-inflammatory cascade .
    Xeligekimab
  • HY-P991260
    CNTO-6785

    		Interleukin Related Infection
    CNTO-6785 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). CNTO-6785 is promising for research of chronic obstructive pulmonary disease (COPD) .
    CNTO-6785
  • HY-P991263
    SCH-900117

    		Interleukin Related Inflammation/Immunology
    SCH-900117 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). SCH-900117 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis .
    SCH-900117
  • HY-P991264
    ZL-1102

    		Interleukin Related Inflammation/Immunology
    ZL-1102 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). ZL-1102 is promising for research of autoimmune diseases such as psoriasis and rheumatoid arthritis .
    ZL-1102
  • HY-P991262
    QX-002N

    		Interleukin Related Inflammation/Immunology
    QX-002N is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). QX-002N is promising for research of inflammatory diseases .
    QX-002N
  • HY-P991595
    HB-0017

    		Interleukin Related Inflammation/Immunology
    HB-0017 is a humanized IgG1κ monoclonal antibody inhibitor, targeting IL-17A. HB-0017 inhibits the IL-6 secretion induced by IL-17A with an IC50 of 2.09 nM. HB-0017 significantly decreases ear thickness in Imiquimod (HY-B0180)-induced psoriasis-like mice model and alleviates inflammations in IL-17A-induced arthritis and air pouch mice model. The isotype control for the HB-0017 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
    HB-0017
  • HY-153276
    Androgen receptor-IN-5

    		Androgen Receptor Cancer
    Androgen receptor-IN-5 is an androgen receptor inhibitor with potent anticancer effects. Androgen receptor-IN-5 also inhibits the production of IL-17A, IL- 17F and INF-γ (WO2023281097A1,Example 1/1) .
    Androgen receptor-IN-5
  • HY-164826
    Acetyl zingerone

    		Interleukin Related Inflammation/Immunology
    Acetyl zingerone is a new multifunctional skincare ingredient that protects melanocytes from ongoing DNA damage. Acetyl zingerone inhibits matrix metalloproteinases and suppresses the expression of the IL-17A target genes, having anti-inflammatory and antioxidant activities .
    Acetyl zingerone
  • HY-P991261
    CJM-112

    		Interleukin Related Inflammation/Immunology
    CJM-112 is a humanized monoclonal antibody inhibitor targeting interleukin-17A (IL-17A). CJM-112 is promising for research of inflammatory diseases, such as hidradenitis suppurativa associated with abnormal IL-17A-related pathways .
    CJM-112
  • HY-170611
    IL-17-IN-3

    		Interleukin Related Inflammation/Immunology
    IL-17-IN-3 (compound 11) is an IL-17A inhibitor with an IC50 value of 35 nM. IL-17-IN-3 exhibits no adverse effects in a rat tolerability study after a four-day administration of up to 300 mg/kg/day .
    IL-17-IN-3
  • HY-152851
    Izumerogant

    IMU-935

    		 ROR Others Cancer
    Izumerogant (IMU-935) is an inverse agonist of retinoid-related orphan receptor-gamma (RORγ). Izumerogant (compound 123) also potently inhibits IL-17A, IL-17F and IFN-γ activity with IC50s <50 nM .
    Izumerogant
  • HY-139780
    JNJ-61803534

    		ROR Inflammation/Immunology
    JNJ-61803534 is a potent and orally active RORγt inverse agonist with an IC50 of 9.6  nM. JNJ-61803534 has anti-inflammatory activity. JNJ-61803534 inhibits IL-17A production in human CD4+ T cells under Th17 differentiation conditions .
    JNJ-61803534
  • HY-168084
    IL-17-IN-1

    		Interleukin Related Inflammation/Immunology
    IL-17-IN-1 (26) is an orally active IL-17 inhibitor, with IC50 values of 0.013 μM and 0.004 μM for IL-17A and IL-6 release, respectively. IL-17-IN-1 (26) effectively reduces knee swelling in a rat arthritis model .
    IL-17-IN-1
  • HY-169007
    STAT3-IN-34

    		STAT Inflammation/Immunology
    STAT3-IN-34 (Compound 15E) is an inhibitor for STAT3, and inhibits the nuclear translocation and transcriptional regulator activity of STAT3. STAT3-IN-34 inhibits the proliferation of cell HaCaT with IC50 of 0.008 μM. STAT3-IN-34 inhibits IL-17A expression and ameliorates Imiquimod (HY-B0180)-induced psoriasis in mice .
    STAT3-IN-34
  • HY-162490
    TF-S14

    		ROR Inflammation/Immunology
    TF-S14 is a reverse agonist of RORγt. TF-S14 reduces Th17 cell-associated cytokine production, including IL-17A, IL-21, and IL-22 by binding to and inhibiting RORγt activity. TF-S14 can be used in the study of autoimmune diseases and rejection in allotransplantation .
    TF-S14
  • HY-107390A
    AX-024 hydrochloride
    1 Publications Verification

    		 TNF Receptor Interleukin Related IFNAR Inflammation/Immunology Cancer
    AX-024 hydrochloride is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC50 ~1 nM. AX-024 hydrochloride modulates cell signaling by targeting SH3 domains. AX-024 hydrochloride has low-acute toxicity and high potency and selectivity, and strongly inhibit the production of IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.
    AX-024 hydrochloride
  • HY-107390
    AX-024
    1 Publications Verification

    		 TNF Receptor Interleukin Related IFNAR Inflammation/Immunology Cancer
    AX-024 is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC50 ~1 nM. AX-024 modulates cell signaling by targeting SH3 domains. AX-024 has low-acute toxicity and high potency and selectivity, and strongly inhibit the production of IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.
    AX-024
  • HY-15826
    SGC-CBP30
    Maximum Cited Publications
    15 Publications Verification

    		 Epigenetic Reader Domain Histone Acetyltransferase Inflammation/Immunology Cancer
    SGC-CBP30 is a potent and highly selective CBP/p300 bromodomain (Kds of 21 nM and 32 nM for CBP and p300, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain of BRD4 [BRD4(1)] bound. SGC-CBP30 strongly reduces secretion of IL-17A in Th17 cells and has anti-inflammatory effects .
    SGC-CBP30
  • HY-N11768
    4-Methoxylonchocarpin

    		NF-κB Interleukin Related Toll-like Receptor (TLR) Inflammation/Immunology
    4-Methoxylonchocarpin is an orally active anti-inflammatory agent. 4-methoxylonchocarpin inhibits the binding of LPS to Toll-like Receptor (TLR) TLR4 to inhibit NF-κB activation and TNF Receptor and IL-6 expression. 4-Methoxylonchocarpin also inhibits the phosphorylation of TGF-beta activated kinase 1 and TNBS-induced expression of IL-1β, IL-17A, and TNF. 4-methoxylonchocarpin can improve 2,4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis mouse model .
    4-Methoxylonchocarpin
  • HY-103637
    Vimirogant

    VTP-43742

    		 ROR Inflammation/Immunology
    Vimirogant (VTP-43742) is a potent, selective, and orally active RORγt inhibitor (Ki=3.5 nM; IC50=17 nM). Vimirogant exhibits >1000-fold selectivity versus the RORα and RORβ isotypes. Vimirogant inhibits Th17 differentiation and IL-17A secretion from mouse splenocytes (IC50=57 nM) without affecting Th1, Th2, or Treg cell differentiation. Vimirogant has the potential for autoimmune disorders research .
    Vimirogant
  • HY-103637A
    Vimirogant hydrochloride
    1 Publications Verification

    VTP-43742 hydrochloride

    		 ROR Inflammation/Immunology
    Vimirogant (VTP-43742) hydrochloride is a potent, selective, and orally active RORγt inhibitor (Ki=3.5 nM; IC50=17 nM). Vimirogant hydrochloride exhibits >1000-fold selectivity versus the RORα and RORβ isotypes. Vimirogant hydrochloride inhibits Th17 differentiation and IL-17A secretion from mouse splenocytes (IC50=57 nM) without affecting Th1, Th2, or Treg cell differentiation. Vimirogant hydrochloride has the potential for autoimmune disorders research .
    Vimirogant hydrochloride
  • HY-155243
    12R-LOX-IN-1

    		DNA/RNA Synthesis Inflammation/Immunology
    12R-LOX-IN-1 (Compound 4a) is a 12R-LOX inhibitor (IC50: 28.25 μM). 12R-LOX-IN-1 inhibits the hyper-proliferative state and colony forming potential of Imiquimod (HY-B0180)-induced psoriatic keratinocytes. 12R-LOX-IN-1 inhibits reactive oxygen species, Ki67, IL-17A, TNF-α and IL-6 production. 12R-LOX-IN-1 can be used for antipsoriatic research .
    12R-LOX-IN-1
  • HY-155244
    12R-LOX-IN-2

    		Lipoxygenase DNA/RNA Synthesis Inflammation/Immunology
    12R-LOX-IN-2 (compound 7b) is an inhibitor of 12R-lipoxygenase (12R-LOX). 12R-LOX-IN-2 inhibits imiquimod (IMQ)-induced hyperproliferation of psoriatic keratinocytes and suppresses colony formation. 12R-LOX-IN-2 also reduced the protein level of Ki67 and the mRNA expression of IL-17A in IMQ-induced cells. 12R-LOX-IN-2 can be used in research into psoriasis and other skin-related inflammatory diseases .
    12R-LOX-IN-2
  • HY-168971
    Paeoniflorin-6′-O-benzene sulfonate

    CP-25

    		 IFNAR STAT TNF Receptor Interleukin Related CXCR JAK G Protein-coupled Receptor Kinase (GRK) Inflammation/Immunology
    Paeoniflorin-6′-O-benzene sulfonate (CP-25) is the inhibitor for G protein-coupled receptor kinase 2 (GRK2) that inhibits the translocation of GRK2 to the cell membrane, inhibits JAK1/STAT3 signaling pathway. Paeoniflorin-6′-O-benzene sulfonate inhibits IL-17A/CXCL2-induced proliferation of HaCaT. Paeoniflorin-6′-O-benzene sulfonate reduces the levels of inflammatory factors and chemokines such as IL-17A, IL-17F, IFN-γ, TNF-α, IL-22, IL-23, CXCL2, CXCL3 and CXCL9, alleviates Imiquimod (HY-B0180)-induced psoriasis in mouse model .
    Paeoniflorin-6′-O-benzene sulfonate
  • HY-155830
    Morcamilast

    ME3183; PDE4-IN-14

    		 Phosphodiesterase (PDE) Interleukin Related Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Morcamilast (ME3183) is a selective and orally active PDE4 inhibitor, with IC50s of 1.28 nM (PDE4A1A), 2.33 nM (PDE4B1), and 1.63 nM (PDE4D2) respectively. Morcamilast shows weak inhibition of PDEs other than PDE4s Morcamilast is an anti-inflammatory agent and inhibits LPS (HY-D1056)-induced release of TNF-α, IL-12/23p40, IL-23, and IL-17A in human PBMCs and T cells. Morcamilast has antipruritic effect and can be used in the study of psoriasis, atopic dermatitis, and other inflammatory diseases .
    Morcamilast

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: